National Academies Press: OpenBook
« Previous: Appendix A: Workshop Statement of Task
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×

Appendix B
Workshop Agenda

The Role of Digital Health Technologies in Drug Development: A Workshop

TUESDAY, March 24, 2020

10:00 a.m. (EST) Welcome
Robert Califf, Verily Life Sciences
Geoffrey Ginsburg, Duke University School of Medicine
Opening Remarks
Jennifer Goldsack, Digital Medicine Society
Joseph Menetski, Foundation for the National Institutes of Health
Briefing: Ethical Considerations
10:15 a.m. Ethicist Perspective
Camille Nebeker, University of California, San Diego

Session I: Digital Tools for Characterizing Disease

Effy Vayena, Health Ethics and Policy Lab, ETH Zurich, Moderator

10:45 a.m. Nonprofit Perspective/Platform Research Perspective
Larsson Omberg, Sage Bionetworks
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
National Institutes of Health Perspective
Chris Lunt, All of Us Research Program, National Institutes of Health
Patient Engagement Perspective
Alicia Staley, Medidata Solutions
Developer Perspective
Luca Foschini, Evidation Health
11:25 a.m. Panel Discussion with Speakers and Workshop Participants
11:45 a.m. Break

Session II: Digital Tools for Recruitment and Safety Trials

Deven McGraw, Ciitizen Corporation, Moderator

12:00 p.m. Regulatory Perspective
Christopher Leptak, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Industry Perspective
Yvonne Yu-Feng Chan, Otsuka Pharmaceutical
Developer Perspective
Chris Benko, Koneksa Health
Academic Perspective
Eric Perakslis, Duke University
12:40 p.m. Panel Discussion with Speakers and Workshop Participants
1:00 p.m. Break
Fireside Chat
Jennifer Goldsack, Digital Medicine Society, Moderator
1:30 p.m. Regulatory Perspective
Amy Abernethy, U.S. Food and Drug Administration

Session III: Digital Tools for Pivotal Trials

Husseini Manji, Janssen Research & Development, LLC, Moderator

Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
2:00 p.m. Industry Perspective
Sean Khozin, Janssen Research & Development, LLC
Developer Perspective
Ritu Kapur, Verily Life Sciences
Regulatory Perspective
Leonard Sacks, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
2:30 p.m. Panel Discussion with Speakers and Workshop Participants
2:50 p.m. Break

Session IV: Digital Tools for Post-Market Surveillance

Christina Silcox, Duke-Margolis Center for Health Policy, Moderator

3:00 p.m. Industry Perspective
Michelle Crouthamel, AbbVie Inc.
Patient Engagement Perspective
Sally Okun, UnitedHealth Group Research & Development
Clinician/Health System Perspective
Edmondo Robinson, Moffitt Cancer Center
3:30 p.m. Panel Discussion with Speakers and Workshop Participants
Key Reflections and Next Steps
3:45 p.m. Key Reflections and Next Steps
Jennifer Goldsack, Digital Medicine Society
Joseph Menetski, Foundation for the National Institutes of Health
4:15 p.m. Adjourn
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×

This page intentionally left blank.

Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
Page 101
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
Page 102
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
Page 103
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25850.
×
Page 104
Next: Appendix C: Planning Committee Biographical Sketches »
The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop Get This Book
×
Buy Paperback | $65.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

On March 24, 2020, a 1-day public workshop titled The Role of Digital Health Technologies in Drug Development was convened by the National Academies of Sciences, Engineering, and Medicine. This workshop builds on prior efforts to explore how virtual clinical trials facilitated by digital health technologies (DHTs) might change the landscape of drug development. To explore the challenges and opportunities in using DHTs for improving the probability of success in drug R&D, enabling better patient care, and improving precision medicine, the workshop featured presentations and panel discussions on the integration of DHTs across all phases of drug development. Throughout the workshop, participants considered how DHTs could be applied to achieve the greatest impact—and perhaps even change the face of how clinical trials are conducted—in ways that are also ethical, equitable, safe, and effective. This publication summarizes the presentations and discussions from the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!